BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

Matica Bio Partners with VaxDome to Advance Novel Intranasal Antiviral Vaccine Platform into Clinical Trials

Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is partnering with Texas-based biotec...

July 08, 2026 | News

The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?

In Songdo and Bengaluru, the numbers finally look like the ones the region was promised a decade ago. Celltrion closed 2025 with revenue above ₩4 trillio...

July 07, 2026 | Analysis

Samsung Biologics Accelerates Sustainability Strategy with Stronger ESG Performance

Advanced environmental performance through renewable energy transition and enhanced carbon transparency Strengthened sustainability management and suppl...

July 02, 2026 | News

Lonza Expands Commercial ADC Payload-Linker Manufacturing at Visp to Support Growing Oncology Pipeline

Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market Investment...

July 01, 2026 | News

Icosagen Completes €45 Million Expansion to Deliver End-to-End Biologics Development and GMP Manufacturing at a Single Site

Estonia-based biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and man...

July 01, 2026 | News

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires

For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...

June 25, 2026 | Analysis

WuXi Biologics Achieves First GMP Production at Shanghai MFG17, Expanding Global Biologics Manufacturing Capacity

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance f...

June 25, 2026 | News

Avance Clinical Expands APAC And China Operations To Accelerate Global Biotech Trials

Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pacif...

June 22, 2026 | News

Pelago Bioscience Acquires RG Discovery to Create Integrated Chemistry-to-Biology Drug Discovery Platform

Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement as...

June 17, 2026 | News

Chime Biologics Expands Manufacturing Capacity With New GMP-2 Facility And AI Powered Megafactory Vision

Chime Biologics’ manufacturing expansion builds on a decade of collaboration enabled by Cytiva’s modular manufacturing platform ...

June 10, 2026 | News

WuXi Biologics Completes Topping Out of Singapore Drug Product Facility

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the toppi...

June 08, 2026 | News

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

In October 2025, Eli Lilly announced it would build the most powerful supercomputer ever owned by a drug company. By February 2026, “LillyPod” ...

June 02, 2026 | Analysis

WuXi Vaccines Secures Second ANVISA GMP Certification To Accelerate Brazil Dengue Vaccine Manufacturing

WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced that...

May 27, 2026 | News

Stay Connected